154 related articles for article (PubMed ID: 34596016)
1. Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021.
Martínez-Baz I; Trobajo-Sanmartín C; Miqueleiz A; Guevara M; Fernández-Huerta M; Burgui C; Casado I; Portillo ME; Navascués A; Ezpeleta C; Castilla J; ;
Euro Surveill; 2021 Sep; 26(39):. PubMed ID: 34596016
[TBL] [Abstract][Full Text] [Related]
2. [Effectiveness of vaccines against SARS-CoV-2 used in Spain: infection, hospitalization and mortality in people aged fifty/fifty-nine.].
Monge S; Mazagatos C; Olmedo C; Rojas-Benedicto A; Simón F; Vega-Piris L; Sierra MJ; Limia A; Larrauri A
Rev Esp Salud Publica; 2022 Sep; 96():. PubMed ID: 36052820
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021.
Martínez-Baz I; Miqueleiz A; Casado I; Navascués A; Trobajo-Sanmartín C; Burgui C; Guevara M; Ezpeleta C; Castilla J;
Euro Surveill; 2021 May; 26(21):. PubMed ID: 34047271
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021.
Kissling E; Hooiveld M; Martínez-Baz I; Mazagatos C; William N; Vilcu AM; Kooijman MN; Ilić M; Domegan L; Machado A; de Lusignan S; Lazar M; Meijer A; Brytting M; Casado I; Larrauri A; Murray JK; Behillil S; de Gier B; Mlinarić I; O'Donnell J; Rodrigues AP; Tsang R; Timnea O; de Lange M; Riess M; Castilla J; Pozo F; Hamilton M; Falchi A; Knol MJ; Kurečić Filipović S; Dunford L; Guiomar R; Cogdale J; Cherciu C; Jansen T; Enkirch T; Basile L; Connell J; Gomez V; Sandonis Martín V; Bacci S; Rose AM; Pastore Celentano L; Valenciano M; ;
Euro Surveill; 2022 May; 27(21):. PubMed ID: 35620997
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of the Comirnaty and the Vaxzevria vaccines in preventing SARS-CoV-2 infection among residents in Lazio region (Italy).
Fano V; Crielesi A; Coviello E; Fabiani M; Salvatore Miglietta A; Colaiocco G; Moretti I; Pasqua C; Vivaldi F; De Angelis G; Cerimele M
Vaccine; 2022 Apr; 40(18):2540-2545. PubMed ID: 35341646
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 updates: Moderna COVID-19 vaccine (Spikevax) gains full licensure.
Med Lett Drugs Ther; 2022 Feb; 64(1644):32. PubMed ID: 35175715
[No Abstract] [Full Text] [Related]
7. Effect of COVID-19 vaccination on the SARS-CoV-2 transmission among social and household close contacts: A cohort study.
Martínez-Baz I; Miqueleiz A; Egüés N; Casado I; Burgui C; Echeverría A; Navascués A; Fernández-Huerta M; García Cenoz M; Trobajo-Sanmartín C; Guevara M; Ezpeleta C; Castilla J
J Infect Public Health; 2023 Mar; 16(3):410-417. PubMed ID: 36724697
[TBL] [Abstract][Full Text] [Related]
8. Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), the Netherlands, August to September 2021.
de Gier B; Andeweg S; Backer JA; ; Hahné SJ; van den Hof S; de Melker HE; Knol MJ;
Euro Surveill; 2021 Nov; 26(44):. PubMed ID: 34738514
[TBL] [Abstract][Full Text] [Related]
9. Vaccine effectiveness against SARS-CoV-2 transmission and infections among household and other close contacts of confirmed cases, the Netherlands, February to May 2021.
de Gier B; Andeweg S; Joosten R; Ter Schegget R; Smorenburg N; van de Kassteele J; ; Hahné SJ; van den Hof S; de Melker HE; Knol MJ;
Euro Surveill; 2021 Aug; 26(31):. PubMed ID: 34355689
[TBL] [Abstract][Full Text] [Related]
10. Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021.
Tran Kiem C; Andronico A; Bosetti P; Paireau J; Alter L; Boëlle PY; Fontanet A; Lévy-Bruhl D; Cauchemez S
Euro Surveill; 2021 Jul; 26(26):. PubMed ID: 34212840
[TBL] [Abstract][Full Text] [Related]
11. Comparative Immunogenicity of COVID-19 Vaccines in a Population-Based Cohort Study with SARS-CoV-2-Infected and Uninfected Participants.
Peterhoff D; Einhauser S; Beileke S; Niller HH; Günther F; Schachtner M; Asbach B; Steininger P; Tenbusch M; Peter AS; Gessner A; Burkhardt R; Heid IM; Wagner R; Überla K
Vaccines (Basel); 2022 Feb; 10(2):. PubMed ID: 35214782
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 vaccine comparison chart.
Med Lett Drugs Ther; 2021 Apr; 63(1621):e1-e11. PubMed ID: 35081102
[No Abstract] [Full Text] [Related]
13. Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel.
Swift MD; Breeher LE; Tande AJ; Tommaso CP; Hainy CM; Chu H; Murad MH; Berbari EF; Virk A
Clin Infect Dis; 2021 Sep; 73(6):e1376-e1379. PubMed ID: 33900384
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 vaccine reactogenicity - A cohort event monitoring study in the Netherlands using patient reported outcomes.
Rolfes L; Härmark L; Kant A; van Balveren L; Hilgersom W; van Hunsel F
Vaccine; 2022 Feb; 40(7):970-976. PubMed ID: 35067381
[TBL] [Abstract][Full Text] [Related]
15. A rational strategy to support approved COVID-19 vaccines prioritization.
Burgos-Salcedo J
Hum Vaccin Immunother; 2021 Oct; 17(10):3474-3477. PubMed ID: 34114939
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
18. In brief: Third dose of mRNA-based COVID-19 vaccines for immunocompromised persons.
Med Lett Drugs Ther; 2021 Sep; 63(1633):145-146. PubMed ID: 34550960
[No Abstract] [Full Text] [Related]
19. COVID-19 update:Booster dose of the Pfizer vaccine for children 5-11 years old.
Med Lett Drugs Ther; 2022 Jun; 64(1652):94. PubMed ID: 35657366
[No Abstract] [Full Text] [Related]
20. COVID-19 vaccine effectiveness among the staff of the Bologna Health Trust, Italy, December 2020-April 2021.
Giansante C; Stivanello E; Perlangeli V; Ferretti F; Marzaroli P; Musti MA; Pizzi L; Resi D; Saraceni S; Pandolfi P
Acta Biomed; 2021 Sep; 92(4):e2021270. PubMed ID: 34487060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
